Elutia (ELUT) Cash from Financing Activities (2019 - 2026)
Elutia (ELUT) posted Cash from Financing Activities of $3000.0 for Q1 2026, up 100.01% sequentially from -$23.1 million in Q4 2025, and down 99.98% YoY from $13.3 million in Q1 2025.
Elutia (ELUT) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Elutia has reported Cash from Financing Activities for 8 years, with the latest figure at $3000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 99.98% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.9 million (down 169.43% YoY) and the FY2025 annual result came in at -$10.6 million, down 162.23% from the prior year.
- Cash from Financing Activities grew to $3000.0 in Q1 2026 per ELUT's latest filing, from -$23.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $14.3 million in Q4 2022 and troughed at -$23.1 million in Q4 2025.
- A 5-year average of $1.4 million and a median of -$151000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 51610.53% in 2024, then sank 15223.18% in 2025.
- Over 5 years, Cash from Financing Activities stood at $14.3 million in 2022, then slumped by 104.87% to -$695000.0 in 2023, then jumped by 78.27% to -$151000.0 in 2024, then tumbled by 15223.18% to -$23.1 million in 2025, then soared by 100.01% to $3000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $3000.0, -$23.1 million, and -$262000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Elutia | 40.75 Mn | 20.85 Mn | 1.45 Mn | -40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | -23.14 Mn |
| Dec 31, 2025 | -23.14 Mn |
| Sep 30, 2025 | -262,000.00 |
| Sep 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -516,000.00 |
| Jun 30, 2025 | -516,000.00 |
| Mar 31, 2025 | 13.28 Mn |
| Mar 31, 2025 | 13.28 Mn |
| Dec 31, 2024 | -151,000.00 |
| Dec 31, 2024 | -151,000.00 |
| Sep 30, 2024 | 11.53 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | 9.79 Mn |
| Jun 30, 2024 | 9.79 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -695,000.00 |
| Dec 31, 2023 | -695,000.00 |